Challenges and Prospects for Cell Therapy Regulation in China
- 25 October 2025
- book chapter
- Published by Springer Nature
- Vol. 1486, 67-77
Abstract
The development of advanced cell-based intervention in China has been rapid, yet it faces a multitude of regulatory challenges. This article comprehensively analyzes the current state and developmental trajectory of the regulatory framework for advanced cell-based intervention in China. The regulation of stem cells and other cell-based interventions in China has undergone multi-phase development, resulting in a relatively well-established regulatory framework that emphasizes pre-clinical research, Good Manufacturing Practices (GMP), and stringent review processes. However, the jurisdiction still confronts several challenges in advanced cell-based intervention regulation. To address these challenges, future regulatory directions in China may include clarifying the drug status of advanced cell-based intervention products, improving technical evaluation systems, establishing risk classification and tiered management systems, strengthening ethical review mechanisms, enhancing the standardization of clinical research, optimizing industrial chain links, and establishing knowledge-sharing platforms.Keywords
This publication has 28 references indexed in Scilit:
- The variability of judicial decisions in the stem cell industry in ChinaCell Stem Cell, 2023
- Stem Cell-Based Therapeutic Approaches in Genetic Diseases2023
- Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMDNew England Journal of Medicine, 2017
- Glioproliferative Lesion of the Spinal Cord as a Complication of “Stem-Cell Tourism”New England Journal of Medicine, 2016
- Toxicity and management in CAR T-cell therapyMolecular Therapy-Oncolytics, 2016
- China announces stem-cell rulesNature, 2015
- China’s stem-cell rules go unheededNature, 2012
- Regulation of Stem Cell-Based Therapies in Canada: Current Issues and ConcernsStem Cell Reviews and Reports, 2012
- Stem-cell therapy faces more scrutiny in ChinaNature, 2009
- Improvement of informed consent and the quality of consent documentsThe Lancet Oncology, 2008